

Poster presentation

Open Access

HIV Escape From Peptide Fusion Inhibitors

Nidhi Gupta*^{‡1}, Emmanuel Desmezieres¹, Russell Vassell¹, Yong He¹, Paul Wingfield² and Carol D Weiss¹

Address: ¹FDA/CBER, 8800 Rockville Pike, Bethesda, Maryland 20892 and ²NIH/NIAMS, 8800 Rockville Pike, Bethesda, Maryland 20892

Email: Nidhi Gupta* - gupta@ncber.fda.gov

* Corresponding author ‡Presenting author

from 2005 International Meeting of The Institute of Human Virology
Baltimore, USA, 29 August – 2 September 2005

Published: 8 December 2005

Retrovirology 2005, **2**(Suppl 1):P34 doi:10.1186/1742-4690-2-S1-P34

HIV envelope glycoprotein (Env) mediates infection by fusing virus with cellular membranes. Fusion inhibitors, a new class of antiretroviral drugs, inhibit HIV infection by binding to gp41 to form a peptide-gp41 6HB that is fusion-incompetent. To understand resistance mechanisms to peptide fusion inhibitors that will aid development of new drugs, we generated an escape-mutant virus against an N-peptide inhibitor. We found that two mutations in gp41, one each in the N- and C- heptad repeats, confer early resistance to the N peptide. These same mutations also confer resistance to a C peptide inhibitor. This is the first report of cross-resistance among peptide fusion inhibitors. Curiously, the N mutation alone or in combination with C mutation also conferred increased sensitivity to soluble CD4 and was associated with faster growth kinetics and larger syncytia. These results suggest global changes in Env involving receptor activation and fusion kinetics. Using thermal denaturation studies, involving N and C peptides containing wild type (N_w or C_w) or resistance residues (N_m or C_m), which self-assemble into a 6HB, we showed that the N mutation improved the energetics of the viral 6HB, however, the energetics of the 6HB formed with the inhibitor and the N and C peptides is not affected. Thus, our results demonstrate a resistance pathway that appears to involve both kinetic and thermodynamic factors that regulate virus entry and work indirectly to reduce the ability of fusion inhibitors to bind Env.